New York, NY -- (SBWIRE) -- 12/31/2012 -- Growing Stock Report iniates an After Hours OTC Volume Watch List and Investor Poll for the following stocks: Elite Pharmaceuticals Inc (OTC:ELTP), USA Graphite Inc (OTC:USGT), mPhase Technologies, Inc. (OTC:XDSL) and ICellceutix Corp (OTC:CTIX)
Elite Pharmaceuticals Inc (OTC:ELTP) 3,260,105 Shares Traded.
Elite Pharmaceuticals, Inc. researches, develops, licenses, and manufactures both new and generic oral controlled-release pharmaceutical products. The Company has pain products in clinical trials and has developed products incorporating therapeutic agents such as cardiovasculars, antidiabetic, cough and cold preparations, and anti-infectives.
Get Poll & ELTP Consensus Report Here: http://www.growingstockreport.com/Survey.aspx?stock=ELTP
USA Graphite Inc (OTC:USGT) 3,237,541 Shares Traded.
USA Graphite Inc., formerly Magnum Oil Inc., is a development-stage company. The Company is focusing its business on acquiring or merging with one or more operating businesses. As of February 29, 2012, the Company had not identified a potential merger or acquisition target. The Company was formed to engage in the magazine publishing business in Malaysia. The Company did not generate any revenue during the fiscal year ended February 29, 2012 (fiscal 2012).
Get Poll & USGT Consensus Report Here: http://www.growingstockreport.com/Survey.aspx?stock=USGT
mPhase Technologies, Inc. (OTC:XDSL) 3,005,088 Shares Traded.
mPhase Technologies, Inc. (mPhase) is a development-stage company. The Company is engaged in developing smart surfaces using materials science engineering, nanotechnology science and the principles of microfluidics and microelectromechanical systems (MEMS). The Company develops products for both commercial and military applications. The Company's flagship product is its Smart NanoBattery providing Power On Command. The platform technology behind the Smart NanoBattery is a porous nanostructured material used to repel and precisely control the flow of liquids. The material has a Smart Surface that can potentially be designed for other products, such as medical devices including heart pacemakers and pumping devices. The Company's wholly-owned subsidiary, AlwaysReady, Inc., to focus on the development of its nanotechnology products.
Get Poll & XDSL Consensus Report Here: http://www.growingstockreport.com/Survey.aspx?stock=XDSL
Cellceutix Corp (OTC:CTIX) 2,634,295 Shares Traded.
Cellceutix Corporation is an early-stage developmental biopharmaceutical company. The Company has acquired exclusive rights to eight different pharmaceutical compound candidates that are designed for treatment of diseases which exist, or may exist in the future. The Company focuses on Phase 1 trial at Dana Farber Cancer Center and Beth Israel Deaconess Hospital for its anti-cancer compound, Kevetrin. In addition, the Company is engaged in pre-clinical testing of two of its product candidates and intends to out-source clinical trials, pre-clinical testing and the manufacture of clinical materials..
Get Poll & CTIX Consensus Report Here: http://www.growingstockreport.com/Survey.aspx?stock=CTIX
GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.GrowingStockReport.com
GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.
Growing Stock Report
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)